Evidence map›Paper›PMID 30223686›Full record

ArticleInterventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences2019

Initial experience with precipitating hydrophobic injectable liquid in cerebral arteriovenous malformations.

Stanimir S Sirakov, Alexander Sirakov, Krasimir Minkin, Hristo Hristov, Kristian Ninov, Marin Penkov, Vasil Karakostov, Kirill Orlov, Anton Gorbatykh, Dmitry Kislitsin and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Stanimir S Sirakov1 Radiology Department, UH St Ivan Rilski, Sofia, Bulgaria.
Alexander Sirakov1 Radiology Department, UH St Ivan Rilski, Sofia, Bulgaria.
Krasimir Minkin1 Radiology Department, UH St Ivan Rilski, Sofia, Bulgaria.
Hristo Hristov2 Neurosurgery Department, UH St Ivan Rilski, Sofia, Bulgaria.
Kristian Ninov2 Neurosurgery Department, UH St Ivan Rilski, Sofia, Bulgaria.
Marin Penkov1 Radiology Department, UH St Ivan Rilski, Sofia, Bulgaria.
Vasil Karakostov2 Neurosurgery Department, UH St Ivan Rilski, Sofia, Bulgaria.
Kirill Orlov3 Department of Interventional Neuroradiology and Neurosurgery, Meshalkin National Medical Research Center, Novosibirsk, Russia.
Anton Gorbatykh3 Department of Interventional Neuroradiology and Neurosurgery, Meshalkin National Medical Research Center, Novosibirsk, Russia.
Dmitry Kislitsin3 Department of Interventional Neuroradiology and Neurosurgery, Meshalkin National Medical Research Center, Novosibirsk, Russia.ORCID https://orcid.org/0000-0002-7721-7449
Radoslav Raychev4 Department of Neurology and Comprehensive Stroke Center, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.
University Hospital St. Ivan Rilski · BGMeshalkin National Medical Research Center · RUUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrecipitating hydrophobic injectable liquid is a newly introduced liquid embolic agent for endovascular embolization with some technical advantages over other liquid embolic agents. We present our initial experience with precipitating hydrophobic injectable liquid in the endovascular treatment of cerebral arteriovenous malformations.

methodsFrom October 2015 to January 2018, 27 patients harboring cerebral arteriovenous malformations underwent endovascular embolization with precipitating hydrophobic injectable liquid 25. Clinical features, angiographic results, procedural details, complications, and follow-up details were retrospectively analyzed.

resultsTwenty-seven patients with cerebral arteriovenous malformations were included. Total obliteration in one endovascular session was confirmed for 14/27 (52%) patients. Partial embolization was attained in 13 patients (48%) in whom staged treatment with following radiosurgery or surgery was planned. No mortality was recorded in this series. Complications during or after the embolization occurred in six of 27 (22.2%) patients.

conclusionIn our initial experience, precipitating hydrophobic injectable liquid has acceptable clinical outcome comparable to other liquid embolic agents. Although this is the largest reported study in arteriovenous malformation treatment with precipitating hydrophobic injectable liquid, further studies are needed to validate its safety and efficacy.

Indexed as

AdolescentAdultAngiography, Digital SubtractionCerebral AngiographyChildDimethyl SulfoxideEmbolization, TherapeuticFemaleHumansIntracranial Arteriovenous MalformationsMaleMiddle AgedRetrospective StudiesTreatment OutcomeDimethyl SulfoxideCerebral arteriovenous malformations (AVMs)embolizationliquid embolic agents (LEAs)precipitating hydrophobic injectable liquid (PHIL)unruptured brain AVMs

Identifiers

PMID30223686
PMCPMC6378517
OpenAlexW2890731337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.